Literature DB >> 20038446

Understanding the quality of protein loaded PLGA nanoparticles variability by Plackett-Burman design.

Ziyaur Rahman1, Ahmed S Zidan, Muhammad J Habib, Mansoor A Khan.   

Abstract

The aim of this investigation was to screen and understand the product variability due to important factors affecting the characteristics CyA-PLGA nanoparticles prepared by O/W emulsification-solvent evaporation method. Independent variables studied were cyclosporine A (CyA) (X(1)), PLGA (X(2)), and emulsifier concentration namely SLS (X(3)), stirring rate (X(4)), type of organic solvent employed (chloroform or dichloromethane, X(5)) and organic to aqueous phase ratio (X(6)). The nanoparticles properties considered were encapsulation efficiency (Y(1)), mean particle size (Y(2)), zeta potential (Y(3)), burst effect (Y(4)) and dissolution efficiency (Y(5)). The statistical analysis of the results allowed determining the most influent factors. The nanoparticles were characterized by scanning electron microscopy (SEM), differential scanning calorimetry (DSC), X-ray powder diffraction (XRD) and Fourier transform infrared (FTIR) spectroscopy. The factors combination showed variability of entrapment efficiency (Y(1)), mean particle size (Y(2)) and zeta potential (Y(3)) from 10.17% to 93.01%, 41.60 to 372.80 nm and 29.60 to 34.90 mV, respectively. Initially, nanoparticles showed burst effect followed by sustained release during the 7-day in vitro release study period. The dissolution efficiency (Y(5)) varied from 52.67% to 84.11%. The nanoparticles revealed Higuchi release pattern and release occurred by coupling of diffusion and erosion. In conclusion, this study revealed the potential of QbD in understanding the effect of formulation and process variables on the characteristics on CyA-PLGA nanoparticles. Copyright 2010. Published by Elsevier B.V.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20038446      PMCID: PMC3086023          DOI: 10.1016/j.ijpharm.2009.12.040

Source DB:  PubMed          Journal:  Int J Pharm        ISSN: 0378-5173            Impact factor:   5.875


  33 in total

1.  Morphology, drug distribution, and in vitro release profiles of biodegradable polymeric microspheres containing protein fabricated by double-emulsion solvent extraction/evaporation method.

Authors:  Y Y Yang; T S Chung; N P Ng
Journal:  Biomaterials       Date:  2001-02       Impact factor: 12.479

2.  Multiple emulsion technology for the design of microspheres containing peptides and oligopeptides.

Authors: 
Journal:  Adv Drug Deliv Rev       Date:  1997-10-13       Impact factor: 15.470

3.  Optimized formulation of high-payload PLGA nanoparticles containing insulin-lauryl sulfate complex.

Authors:  Kai Shi; Fude Cui; Hiromitsu Yamamoto; Yoshiaki Kawashima
Journal:  Drug Dev Ind Pharm       Date:  2009-02       Impact factor: 3.225

4.  Properties and stability of a liquid crystal form of cyclosporine-the first reported naturally occurring peptide that exists as a thermotropic liquid crystal.

Authors:  David Lechuga-Ballesteros; Ahmad Abdul-Fattah; Cynthia L Stevenson; David B Bennett
Journal:  J Pharm Sci       Date:  2003-09       Impact factor: 3.534

5.  Cyclosporine-loaded polycaprolactone nanoparticles: immunosuppression and nephrotoxicity in rats.

Authors:  M C Varela ; M Guzmán; J Molpeceres; M del Rosario Aberturas; D Rodríguez-Puyol; M Rodríguez-Puyol
Journal:  Eur J Pharm Sci       Date:  2001-02       Impact factor: 4.384

6.  Release modulating hydrophilic matrix systems of losartan potassium: optimization of formulation using statistical experimental design.

Authors:  Shruti Chopra; Gayathri V Patil; Sanjay K Motwani
Journal:  Eur J Pharm Biopharm       Date:  2006-09-10       Impact factor: 5.571

7.  Biodegradable progesterone microsphere delivery system for osteoporosis therapy.

Authors:  Q Yang; G Owusu-Ababio
Journal:  Drug Dev Ind Pharm       Date:  2000-01       Impact factor: 3.225

8.  Dosing and safety of cyclosporine in patients with severe brain injury.

Authors:  Jimmi Hatton; Bonnie Rosbolt; Philip Empey; Richard Kryscio; Byron Young
Journal:  J Neurosurg       Date:  2008-10       Impact factor: 5.115

9.  PLGA nanoparticles for oral delivery of cyclosporine: nephrotoxicity and pharmacokinetic studies in comparison to Sandimmune Neoral.

Authors:  J L Italia; D K Bhatt; V Bhardwaj; K Tikoo; M N V Ravi Kumar
Journal:  J Control Release       Date:  2007-02-14       Impact factor: 9.776

10.  Differential interaction of human renal P-glycoprotein with various metabolites and analogues of cyclosporin A.

Authors:  J H Charuk; P Y Wong; R A Reithmeier
Journal:  Am J Physiol       Date:  1995-07
View more
  25 in total

1.  Evaluation of anticancer drug-loaded nanoparticle characteristics by nondestructive methodologies.

Authors:  David Awotwe-Otoo; Ahmed S Zidan; Ziyaur Rahman; Muhammad J Habib
Journal:  AAPS PharmSciTech       Date:  2012-04-26       Impact factor: 3.246

2.  Enhanced L-methionine production by genetically engineered Escherichia coli through fermentation optimization.

Authors:  Hai-Yan Zhou; Wang-Jie Wu; Kun Niu; Yue-Ying Xu; Zhi-Qiang Liu; Yu-Guo Zheng
Journal:  3 Biotech       Date:  2019-02-19       Impact factor: 2.406

3.  Formulation of topical ibuprofen solid lipid nanoparticle (SLN) gel using hot melt extrusion technique (HME) and determining its anti-inflammatory strength.

Authors:  Arvind Bagde; Ketan Patel; Shallu Kutlehria; Nusrat Chowdhury; Mandip Singh
Journal:  Drug Deliv Transl Res       Date:  2019-08       Impact factor: 4.617

4.  Continuous production of fenofibrate solid lipid nanoparticles by hot-melt extrusion technology: a systematic study based on a quality by design approach.

Authors:  Hemlata Patil; Xin Feng; Xingyou Ye; Soumyajit Majumdar; Michael A Repka
Journal:  AAPS J       Date:  2014-10-25       Impact factor: 4.009

5.  Preparation, characterization, and transport of dexamethasone-loaded polymeric nanoparticles across a human placental in vitro model.

Authors:  Hazem Ali; Irina Kalashnikova; Mark Andrew White; Michael Sherman; Erik Rytting
Journal:  Int J Pharm       Date:  2013-07-12       Impact factor: 5.875

6.  Repurposing rosiglitazone, a PPAR-γ agonist and oral antidiabetic, as an inhaled formulation, for the treatment of PAH.

Authors:  Jahidur Rashid; Ahmad Alobaida; Taslim A Al-Hilal; Samia Hammouda; Ivan F McMurtry; Eva Nozik-Grayck; Kurt R Stenmark; Fakhrul Ahsan
Journal:  J Control Release       Date:  2018-04-30       Impact factor: 9.776

7.  Nanomedicine for uterine leiomyoma therapy.

Authors:  Hazem Ali; Gokhan Kilic; Kathleen Vincent; Massoud Motamedi; Erik Rytting
Journal:  Ther Deliv       Date:  2013-02

8.  Respirable controlled release polymeric colloid (RCRPC) of bosentan for the management of pulmonary hypertension: in vitro aerosolization, histological examination and in vivo pulmonary absorption.

Authors:  Lydia A Hanna; Emad B Basalious; Omaima N ELGazayerly
Journal:  Drug Deliv       Date:  2016-11       Impact factor: 6.419

9.  Quality by Design for Development, Optimization and Characterization of Brucine Ethosomal Gel for Skin Cancer Delivery.

Authors:  Tamer A Ismail; Tamer M Shehata; Dalia I Mohamed; Heba S Elsewedy; Wafaa E Soliman
Journal:  Molecules       Date:  2021-06-07       Impact factor: 4.411

10.  Poly ɛ-caprolactone nanoparticles loaded with Uncaria tomentosa extract: preparation, characterization, and optimization using the Box-Behnken design.

Authors:  Ana Ferreira Ribeiro; Ricardo Leite de Oliveira Rezende; Lúcio Mendes Cabral; Valéria Pereira de Sousa
Journal:  Int J Nanomedicine       Date:  2013-01-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.